:

Homeland Security

DoD Awards Morphotek $2.3M to Develop Biowarfare Therapies

DDN

Wednesday, October 3rd, 2007

SHARE:

Morphotek, Inc., a subsidiary of Japanese pharmaceutical company Eisai Co., received $2.3 million in funding from the Department of Defense to support the development of biologic- based monoclonal antibody therapies against biowarfare agents. Under the nine-month contract Morphotek will continue developing the therapies to treat Botulinum neurotoxins. "The further development of these compounds will enable us to advance these leads into clinical studies for validation and registration," says Nicholas Nicolaides, president and CEO of Morphotek.

Congress

House Authorizers Retain Battleship Funding, But Want Nuclear-Power Report

The House Armed Services Committee’s (HASC) Thursday markup of the FY 2027 defense authorization bill rejected an amendment to cut funding for the new Trump-class battleship (BBG(X)), but did agree […]

Congress

HASC Rejects $150 Billion Topline Cut, Iran Cost Transparency Proposals At NDAA Markup

The House Armed Services Committee (HASC) on Thursday rejected a Democrat-led proposal to cut the $1.15 trillion fiscal year 2027 National Defense Authorization Act (NDAA) by $150 billion, as the […]

HASC Wants Pentagon List Of Critical F-35 Technical Data Rights And Estimate Of Cost To Buy Them For Repairs

The House Armed Services Committee (HASC) wants the Pentagon to inform the committee of critical technical data rights for the Lockheed Martin [LMT] F-35 fighter and how much it would […]

Space

NRO Nominee: “We Have To Look Differently At Our Requirements”

The National Reconnaissance Office (NRO) has said that it has launched more than 200 proliferated low Earth orbit satellites in the last two years to supplement the costly high-end systems […]